BridgeBio highlights $1.7 billion cash position, targets three potential US launches by mid-2027
BBIO•Cash position and pipeline outlook
Cash, cash equivalents, and marketable securities totaled $1.7 billion as of June 30, 2026, positioned for three potential US launches by mid-2027.
BBP-418 for LGMD2I/R9 carried a PDUFA date of Nov. 27, 2026; infigratinib for achondroplasia was listed as NDA submitted.
Encaleret for ADH1 carried a PDUFA date of May 8, 2027; Phase 3 work in chronic hypoparathyroidism was underway.
BridgeBio presentation highlights launch momentum for Attruby
BridgeBio presentation highlighted Attruby (acoramidis) launch momentum, citing Q2 2026 net product revenue of $222.4 million.
Estimated Attruby share exceeded 25% of new-to-brand prescriptions, targeting 30%-40% peak share, peak market sales above $4 billion.
